life scienc diagnost tool
except quarter full steam ahead
reiter buy rais price target prior
back strong beat rais result particularli
impress organ revenu growth well strong growth
across busi segment geograph region end market initi
guidanc organ revenu growth tmo typic
initi target meaning compani tmo size believ
reflect better overal outlook enter new year book
addit continu fire cylind term
capit fastest grow end market strengthen
growth china etc execut patheon integr first-year
synergi target track capit deploy strategi near-term
prioriti debt paydown dividend increas share buy-back
guidanc activ pipelin ep guidanc call
growth y/i vs prior consensu growth inclus
 tax reform benefit tax rate reduct continu
remain bullish overal lst sector cap solid
note organ revenu growth rate agil
rate rate
rate
buy pt healthi outlook organ revenu growth
guidanc
msd growth share current trade discount
averag price-to-earnings peer group think valuat closer
peer group averag warrant given tmo industri leadership
model updat revenu ep est y/i
vs prior y/i vs
prior revenu ep est y/i vs
prior y/i vs prior
valuat pt base price-to-earnings
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
exhibit varianc million except per share data
lab product servic
organ revenu growth organ revenu growth full year
strong growth across board particularli bioproduct bioscienc
full year adj om expans bp
organ revenu growth organ revenu growth full year
strong growth across busi
full year adj om expans bp
organ revenu growth organ revenu growth full year
strong growth season product good perform clinic transplant
full year adj om declin bp larg attribut unfavor mix
organ revenu growth organ revenu growth full year
strong growth across busi particularli channel busi clinic trial
includ patheon acquisit
full year adj om declin bp larg attribut unfavor mix
actualstreet estimate btig chang profit gross margin incom oper margin rate incom chang
exhibit end market observ outlook
observ growth constant currenc
hsd msd year
msd msd year
low-teen year
china grew high-teen
low-teen msd year
y/i growth hsd year
strong growth across tmo busi particularli bioproduct clinic trial
outlook msd hsd growth
hsd growth msd year
strong demand mass spectrometri electron microscopi system
outlook lsd msd growth
hsd growth lsd year
strength season busi good demand biomark test
outlook lsd msd growth
msd growth msd year
continu good growth chemic analysi
outlook msd growth
share
tailwind
includ bp dilut patheon
vs
fx tailwind
assum share buyback complet
y/i increas due time project full year patheon impact
anticip receiv custom fund toward capital-expenditure
expect return million dividend increas dividend
announc increas quarterli cash dividend per share
quarterli phase
expect slightli higher
averag year driven time
holiday strong comp
expect phase
fiscal year end dec million except per share scienc diagnost product revenu profit profit develop expens incom non-oper non-oper expens incom tax incom incom analysiscost revenu margin gener administr develop margin tax margin growthlif scienc diagnost product bpssg incom bpsnet incom compani report btig estim
btig cover compani mention report
appendix analyst certif import disclosur
